EXJADE - EXJADE - CT 3381 - English version

Has

Description

Introduction EXJADE 125 mg, dispersible tablets Box of 28 (CIP 376 951-1); box of 84 (CIP 376 952-8) EXJADE 250 mg, dispersible tablets Box of 28 (CIP 376,953-4); box of 84 (CIP 376,9540) EXJADE 500 mg, dispersible tablets Box of 28 (CIP 376,955-7); box of 84 (CIP 376,956-3) Posted on Aug 01 2008 Active substance (DCI) deferasirox ATC Code V03AC03 Laboratory / Manufacturer NOVARTIS PHARMA S.A.S. EXJADE 125 mg, dispersible tablets Box of 28 (CIP 376 951-1); box of 84 (CIP 376 952-8) EXJADE 250 mg, dispersible tablets Box of 28 (CIP 376,953-4); box of 84 (CIP 376,9540) EXJADE 500 mg, dispersible tablets Box of 28 (CIP 376,955-7); box of 84 (CIP 376,956-3) Posted on Aug 01 2008

Sujets

• Médecine

Informations

• Publié par: haute-autorite-sante-traitement-medicamenteux
• Publié le: 20 septembre 2006
• Nombre de lectures: 12
• Licence : En savoir +
  Paternité, pas d'utilisation commerciale, partage des conditions initiales à l'identique
• Langue: English

Extrait

   

   

  The legally binding text is the original French version   TRANSPARENCY COMMITTEE

Opinion

  20 September 2006     EXJADE 125 mg, dispersible tablets Box of 28 (CIP 376 951-1); box of 84 (CIP 376 952-8)   EXJADE 250 mg, dispersible tablets Box of 28 (CIP 376,953-4); box of 84 (CIP 376,9540)   EXJADE 500 mg, dispersible tablets Box of 28 (CIP 376,955-7); box of 84 (CIP 376,956-3)   Applicant : NOVARTIS PHARMA S.A.S.   deferasirox   List I Medicinal product for hospital prescription only Medicinal product requiring special monitoring during treatment   Date of Marketing Authorisation: 28.08.06   Reason for request: Inclusion on the list of medicines reimbursed by French National Insurance and approved for use by hospitals                                         Health Technology Assessment Division 1